Dose-tailoring of FEC adjuvant chemotherapy based on leukopenia is feasible and well tolerated. Toxicity and dose intensity in the Scandinavian Breast Group phase 3 adjuvant Trial SBG 2000-1Per Edlund, Carl Blomqvist, Jonas Bergh et al.|Acta Oncologica|2011Cited by 11
A randomised study of tailored toxicity-based dosage of fluorouracil-epirubicin-cyclophosphamide chemotherapy for early breast cancer (SBG 2000-1)Henrik Lindman, Carl Blomqvist, Michael Andersson et al.|European Journal of Cancer|2018Cited by 4